Related Experiment Video
Updated: Aug 12, 2026
13:19
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Biomarkers associated with prostate cancer progression
H E Zhau1, L L Pisters, M C Hall
1Urology Research Laboratory, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Journal of Cellular Biochemistry. Supplement
|January 1, 1994
Summary
Researchers identified key biomarkers for prostate cancer progression using genetic and epigenetic models. These markers, including c-erbB-2/neu oncogene and vimentin, aid in predicting cancer spread and evaluating human prostate tissues.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Prostate cancer progression involves complex genetic and epigenetic factors.
- Identifying reliable biomarkers is crucial for predicting disease advancement.
- Prostatic epithelial cells are key sites for biomarker expression during carcinogenesis.
Purpose of the Study:
- To identify and validate stage-specific biomarkers for human prostate cancer progression.
- To investigate the role of genetic and epigenetic alterations in prostate cancer metastasis.
- To evaluate potential biomarkers in experimental models and clinical prostate tissues.
Main Methods:
- Development of two experimental models: a genetic model (PC-3 cells with mutated c-erbB-2/neu) and an epigenetic model (LNCaP sublines).
- Extensive characterization of cloned cells from primary and metastatic tumors using cellular, biochemical, immunohistochemical, and molecular techniques.
- Evaluation of defined biomarkers in human prostate tissues obtained from clinical settings.
Main Results:
- The genetic model demonstrated metastasis to soft tissues and skeleton following c-erbB-2/neu oncogene transfection.
- The epigenetic model showed metastasis to lymph nodes and bone from the parental LNCaP cell line.
- Identified potential biomarkers include c-erbB-2/neu oncogene, vimentin, hepatocyte growth factor/scatter factor, c-met oncogene, tumor angiogenesis, and neuroendocrine factors.
Conclusions:
- Established experimental models provide valuable platforms for prostate cancer biomarker discovery.
- Specific molecular markers show promise in predicting prostate cancer progression and metastasis.
- Further validation of these biomarkers is essential for clinical application in prostate cancer management.
